Loading
DESTINY-Gastric02 repeated the trastuzumab deruxtecan study in patients from Europe and the United States, after the first trial had been run only in Japan and Korea, and confirmed that the drug produces meaningful responses in HER2-positive stomach cancer after trastuzumab.
DESTINY-Gastric01 enrolled only East Asian patients, where stomach cancer is treated differently and diagnosed earlier. DESTINY-Gastric02 was a single-arm phase 2 study in the United States and Europe of trastuzumab deruxtecan in 79 patients with HER2-positive gastric or gastro-oesophageal junction cancer that had progressed on a first-line trastuzumab regimen, with the HER2 status re-confirmed on a fresh biopsy. The primary endpoint was confirmed objective response by independent review.
The study confirmed clinically meaningful and durable responses in a Western population, with a safety profile consistent with the earlier trial, supporting the drug's use outside East Asia. The subtype page notes that the response rate was lower than in the Asian trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
79 enrolled.
95% CI 27.3 to 49.6
Source95% CI 30.8 to 53.4
SourceThe full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, HER2-positive gastric cancer, Daiichi Sankyo, Trastuzumab deruxtecan and the tag subtype-trials.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag subtype-trials.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag subtype-trials.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag subtype-trials.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag subtype-trials.
Shares HER2-positive gastric cancer, Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads).
Shares AstraZeneca and the tag subtype-trials.
Shares Gastric & gastro-oesophageal junction cancer and the tag subtype-trials.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/